Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT06446310
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Jieyang People's Hospital, Jieyang, Guangdong, China
🇨🇳Shandong Provincial Hospital, Jinan, Shandong, China
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 378
- Registration Number
- NCT05922436
A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 516
- Registration Number
- NCT05822713
A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT05648669
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath